


NP213 TFA

Cat. No.:	HY-126810A
Molecular Formula:	C ₄₄ H ₈₅ F ₃ N ₂₈ O ₉
Molecular Weight:	1207.32
Sequence:	Cyclo-Arg-Arg-Arg-Arg-Arg-Arg
Sequence Shortening:	Cyclo-RRRRRRR
Target:	Fungal
Pathway:	Anti-infection
Storage:	Sealed storage, away from moisture and light, under nitrogen
	Powder -80°C 2 years
	-20°C 1 year



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

SOLVENT & SOLUBILITY

In Vitro

H₂O : 100 mg/mL (82.83 mM; Need ultrasonic)
 DMSO : 100 mg/mL (82.83 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	0.8283 mL	4.1414 mL	8.2828 mL
	5 mM	0.1657 mL	0.8283 mL	1.6566 mL
	10 mM	0.0828 mL	0.4141 mL	0.8283 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: PBS
Solubility: 100 mg/mL (82.83 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (2.07 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 TFA targets the fungal cytoplasmic membrane and plays its role via membrane perturbation and disruption. NP213 TFA is

	effective and well-tolerated in resolving nail fungal infections ^{[1][2]} .								
IC₅₀ & Target	IC50: fungal ^[1]								
In Vitro	<p>NP213 (500-1000 µg/mL; 18 hours) increases the number of PI-stained <i>T. rubrum</i> NCPF0118 cells in samples. This results suggests that NP213 is fungicidal and the mechanisms of action involved membrane permeabilization^[1].</p> <p>NP213 is against <i>T. rubrum</i> NCPF0118, shows different MIC values against <i>T. rubrum</i> NCPF0118, and the MICs varies depending on the source of the keratin. The MIC values are 16-32 mg/L, 125 mg/L, and 250 mg/L for NP213 in 1640 media containing human nail Keratin, human skin Keratin and Lamb's wool Keratin, respectively^[1]. NP213 TFA (2-3 hours; 0-8 µg/ml) has great activity against clinically relevant yeast, including candida spp, Cryptococcus spp and Trichosporon spp. For all 122 yeast isolates, with the median MIC₁₀₀ values of 1-2 µg/ml^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[3]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Clinically relevant yeast isolates</td> </tr> <tr> <td>Concentration:</td> <td>0 µg/ml; 0.125 µg/ml; 0.25 µg/ml; 0.5 µg/ml; 1 µg/ml; 2 µg/ml; 4 µg/ml; 8 µg/ml</td> </tr> <tr> <td>Incubation Time:</td> <td>2 h, 2.5 h, 4 h</td> </tr> <tr> <td>Result:</td> <td>Decreased isolates growth as a dose-dependent manner.</td> </tr> </table>	Cell Line:	Clinically relevant yeast isolates	Concentration:	0 µg/ml; 0.125 µg/ml; 0.25 µg/ml; 0.5 µg/ml; 1 µg/ml; 2 µg/ml; 4 µg/ml; 8 µg/ml	Incubation Time:	2 h, 2.5 h, 4 h	Result:	Decreased isolates growth as a dose-dependent manner.
Cell Line:	Clinically relevant yeast isolates								
Concentration:	0 µg/ml; 0.125 µg/ml; 0.25 µg/ml; 0.5 µg/ml; 1 µg/ml; 2 µg/ml; 4 µg/ml; 8 µg/ml								
Incubation Time:	2 h, 2.5 h, 4 h								
Result:	Decreased isolates growth as a dose-dependent manner.								
In Vivo	<p>NP213 TFA (25 mg/kg) is well tolerated in mice. In Murine models of acute disseminated candidiasis, NP213 is tolerated and efficacious and exhibits a half-life of approximately 4.5 h^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								

REFERENCES

- [1]. Mercer DK, et al. Improved Methods for Assessing Therapeutic Potential of Antifungal Agents against Dermatophytes and Their Application in the Development of NP213, a Novel Onychomycosis Therapy Candidate. *Antimicrob Agents Chemother.* 2019 Apr 25;63(5). pii
- [2]. Neelabh, et al. Sequential and Structural Aspects of Antifungal Peptides from Animals, Bacteria and Fungi Based on Bioinformatics Tools. *Probiotics Antimicrob Proteins.* 2016 Jun;8(2):85-101.
- [3]. Novamycin®/NP339 Technology Summary

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA